Agriculture currently produces rapid development of molecular biotechnology, which can offer a cheaper way than the manufacture of vaccines and traditional medicine through the mill. Scientists have found that healthy tobacco after modifying genetic factors. Tobacco can be used to treat type 1 diabetes.
European researchers said they had produced tobacco, which contains anti-inflammatory compounds (anti-inflammatory) called interleukin-10 (IL-10) that can help patients with type 1 diabetes are still dependent insulin. A number of agrochemical companies, including Bayer and Syngenta, have been looking for ways to make complex protein drugs in plants, although it requires a slow process.
At this time, most of the medicines and vaccines produced in cell culture and tissue culture. However, Mario Pezzotti of the University of Verona, who led the study published in the journal Tobacco BMC Biotechnology, believes that the tobacco plants grow more efficiently since the world has a low cost to produce protein drugs.
Different types of plants have been studied by a number of scientists around the world, but tobacco is a crop of the most popular in terms of research. "Tobacco is a fantastic plant because it is easy to transform genetically and can easily learn the entire plant from a single cell," Pezzotti said. Group work and put the interests of the tobacco giant, which Philip Morris, which supports plant-based medicine conference in Verona in June.
Pezzotti and colleagues - who received funding for his research from the European Union - now plan to megujicobakan plants to mice with autoimmune diseases to determine its response.
Furthermore, they wanted to test whether the repetition of small doses could help prevent diabetes in people, when given together with other compounds, namely glutamic acid decarboxylase (GAD65), which has also been produced in tobacco plants.
Diamyd, biotechnology companies in Sweden have tested conventional GAD65 vaccine against diabetes during clinical trials.
Molecular agriculture has not produced its first commercial product, although Israel Protalix BioTherapeutics has conducted clinical trials on advanced enzymes for the treatment of Gaucher disease generated by culture of carrot cells. Protalix plans to submit the drug for approval from the United States and Israel.
